Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023
Neurourology and Urodynamics · 2024-08 · 43 (6) · 1447-1457
DOI: 10.1002/nau.25435 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurourology and Urodynamics, online erschienen am 13.03.2024. Verfasst von Tufan Tarcan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Marmara University School of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: Lower Urinary Tract Symptoms, Urodynamics. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben.
Abstract (Originalsprache)
Aims
Lower urinary tract symptoms (LUTS) persist in up to 50% of patients after bladder outflow resistance reduction surgery (BORRS) in men. Our think tank aims to address the predictive factors for persistent LUTS after BORRS and to propose the recommendations for future research to enable improved better patient counseling and selection by more accurate prediction of treatment outcome.
Methods
A think tank of ICI‐RS gathered in 2023, Bristol, UK, to discuss the pre and postsurgical clinical and urodynamic evaluation of men undergoing BORRS and whether it is possible to predict which men will have persistent LUTS after BORRS.
Results
Our think tank agrees that due to the multifactorial, and still not fully understood, etiology of male LUTS it is not possible to precisely predict in many men who will have persistent LUTS after BORRS. However, severe storage symptoms (overactive bladder, OAB) in association with low volume and high amplitude detrusor overactivity and low bladder capacity in preoperative urodynamics, increase the likelihood of persistent OAB/storage symptoms after BORRS. Furthermore, patients who are clearly obstructed and have good bladder contractility on preoperative pressure flow studies do better postoperatively compared to their counterparts. However, the benefit of pressure flow studies is decreased in patients who do not acceptably void during the study. Poor voiding after BORRS may occur due to persistent obstruction or detrusor underactivity.
Conclusion
Future research is needed to increase our understanding of why male LUTS persist after surgery, and to enable better patient selection and more precise patient counseling before BORRS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Marmara University School of Medicine, Istanbul, Turkey.
- Department of Urology, Koc University School of Medicine, Istanbul, Turkey.
- Bristol Urological Institute, Southmead Hospital, Bristol, UK.
- Department of Urology, Guy's and St Thomas' NHS Foundation Trust & King's College London, London, UK.
- Department of Urology, Apollo Hospital, Hyderabad, India.
- College of Medicine, Department of Urology, University of Illinois at Chicago, Chicago, Illinois, USA.
ORCID-Profile: Tufan Tarcan
Zitieren
APA
Tarcan, T., Hashim, H., Malde, S., Sinha, S., Sahai, A., Acar, O., Selai, C., Agro, E. F., Abrams, P., & Wein, A. (2024). Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023. Neurourology and Urodynamics, 43(6), 1447-1457. https://doi.org/10.1002/nau.25435
Vancouver
Tarcan T, Hashim H, Malde S, Sinha S, Sahai A, Acar O, et al. Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023. Neurourology and Urodynamics. 2024;43(6):1447-1457. doi:10.1002/nau.25435
BibTeX
@article{Tarcan2024,
author = {Tarcan, Tufan and Hashim, Hashim and Malde, Sachin and Sinha, Sanjay and Sahai, Arun and Acar, Omer and Selai, Caroline and Agro, Enrico Finazzi and Abrams, Paul and Wein, Alan},
title = {Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023},
journal = {Neurourology and Urodynamics},
year = {2024},
volume = {43},
number = {6},
pages = {1447--1457},
doi = {10.1002/nau.25435}
}
EUVIMED